| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of Urology [T. H., T. S., R. S., L. W., K. S., S. S., T. A., N. T., N. S., T. K.], Hygiene [Y. W., A. K.], Clinical and Laboratory Medicine [J. C.], Akita University School of Medicine, Akita 010-8543, and Department of Urology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507 [O. O.], Japan
Recent studies have suggested that vitamin D is an important determinant of prostate cancer risk and inherited polymorphisms in the 3'-untranslated region (3'UTR) of the vitamin D receptor (VDR) gene are associated with the risk and progression of prostate cancer. This study was conducted to explore the association of VDR gene polymorphisms with prostate cancer risk in Japanese men who are considered to be much less influenced by environmental risk factors for prostate cancer. We studied 222 prostate cancer patients, 209 benign prostatic hyperplasia (BPH) patients, 128 male controls who were over 60 years old and without any evidence of prostate cancer or BPH, and 198 female controls. A PCR-RFLP method was used to determine three VDR gene polymorphisms in the 3'UTR characterized by restriction enzymes BsmI, ApaI and TaqI. In the BsmI polymorphism, heterozygosity or homozygosity for the absence of the BsmI restriction site was associated with one-third the risk of prostate cancer (P < 0.0001; odds ratio, 3.31; 95% confidence interval, 2.055.32) and with one-half the risk of BPH (P < 0.005; odds ratio, 2.07; 95% confidence interval, 1.333.22) compared with the male controls. The TaqI and ApaI polymorphisms did not show any significant association with either prostate cancer or BPH. The results indicate that the BsmI polymorphism in the VDR gene plays a significant role in protection against prostate cancer and BPH. Because of the racial difference in the strength of the linkage disequilibrium between the three polymorphisms, additional studies are required to apply the present results to other racial-ethnic groups.
This article has been cited by other articles:
![]() |
K. KOSTNER, N. DENZER, C. S.L. MULLER, R. KLEIN, W. TILGEN, and J. REICHRATH The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of the Literature Anticancer Res, September 1, 2009; 29(9): 3511 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Raimondi, H. Johansson, P. Maisonneuve, and S. Gandini Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk Carcinogenesis, July 1, 2009; 30(7): 1170 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Onen, A. Ekmekci, M. Eroglu, E. Konac, S. Yesil, and H. Biri Association of Genetic Polymorphisms in Vitamin D Receptor Gene and Susceptibility to Sporadic Prostate Cancer Experimental Biology and Medicine, December 1, 2008; 233(12): 1608 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tuohimaa, L. Tenkanen, H. Syvala, S. Lumme, T. Hakulinen, J. Dillner, and M. Hakama Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 302 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Cicek, X. Liu, F. R. Schumacher, G. Casey, and J. S. Witte Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2549 - 2552. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tsuchiya, L. Wang, H. Suzuki, T. Segawa, H. Fukuda, S. Narita, M. Shimbo, T. Kamoto, K. Mitsumori, T. Ichikawa, et al. Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer J. Clin. Oncol., May 1, 2006; 24(13): 1982 - 1989. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr, and M. F. Holick The Role of Vitamin D in Cancer Prevention Am J Public Health, February 1, 2006; 96(2): 252 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kamoto, Y. Isogawa, Y. Shimizu, S. Minamiguchi, H. Kinoshita, Y. Kakehi, K. Mitsumori, S. Yamamoto, T. Habuchi, T. Kato, et al. Association of a Genetic Polymorphism of the E-cadherin Gene with Prostate Cancer in a Japanese Population Jpn. J. Clin. Oncol., March 1, 2005; 35(3): 158 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Oakley-Girvan, D. Feldman, T. R. Eccleshall, R. P. Gallagher, A. H. Wu, L. N. Kolonel, J. Halpern, R. R. Balise, D. W. West, R. S. Paffenbarger Jr., et al. Risk of Early-Onset Prostate Cancer in Relation to Germ Line Polymorphisms of the Vitamin D Receptor Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1325 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, T. Habuchi, N. Tsuchiya, K. Mitsumori, C. Ohyama, K. Sato, H. Kinoshita, T. Kamoto, A. Nakamura, O. Ogawa, et al. Insulin-like Growth Factor-binding Protein-3 Gene -202 A/C Polymorphism Is Correlated with Advanced Disease Status in Prostate Cancer Cancer Res., August 1, 2003; 63(15): 4407 - 4411. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, A. Shibata, J. E. McNeal, T. A. Stamey, D. Feldman, and D. M. Peehl Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 23 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF] |
||||
![]() |
A. P. Chokkalingam, K. A. McGlynn, Y.-T. Gao, M. Pollak, J. Deng, I. A. Sesterhenn, F. K. Mostofi, J. F. Fraumeni Jr., and A. W. Hsing Vitamin D Receptor Gene Polymorphisms, Insulin-like Growth Factors, and Prostate Cancer Risk: A Population-based Case-Control Study in China Cancer Res., June 1, 2001; 61(11): 4333 - 4336. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al. Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect Cancer Res., October 1, 2000; 60(20): 5710 - 5713. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |